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ABSTRACT  
Monoacylglycerol lipase (MAGL) inhibitors are considered potential therapeutic agents for a variety 
of pathological conditions, including several types of cancer. Many MAGL inhibitors are reported in 
literature; however, most of them showed an irreversible mechanism of action, which caused 
important side effects. The use of reversible MAGL inhibitors has been only partially investigated so 
far, mainly because of the lack of compounds with good MAGL reversible inhibition properties. In 
this study, starting from the (4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)methanone 
(CL6a) lead compound that showed a reversible mechanism of MAGL inhibition (Ki = 8.6 µM), we 
started its structural optimization and we developed a new potent and selective MAGL inhibitor (17b, 
Ki = 0.65 µM). Furthermore, modeling studies suggested that the binding interactions of this 
compound replace a structural water molecule reproducing its H-bonds in the MAGL binding site, 
thus identifying a new key anchoring point for the development of new MAGL inhibitors. 
 
INTRODUCTION 
Among the different endogenous lipids with endocannabinoid-like activity, anandamide (AEA) and 
2-arachidonoylglycerol (2-AG) are the two most important endogenous ligands that are able to 
activate the G protein-coupled cannabinoid receptors, CB1 and CB2.
1 These endocannabinoids are 
produced on demand through stimulus-dependent cleavage of phospholipid precursors and they 
modulate multiple physiological processes including pain, inflammation, appetite, memory, and 
emotion and their signaling functions terminate by enzymatic hydrolysis.2, 3 In the nervous system, 
2-AG is produced by phospholipase C and diacylglycerol lipase and it is deactivated through 
hydrolysis mediated by monoacylglycerol lipase (MAGL). Because of the prominent role in 2-AG 
degradation, selective inactivation of MAGL represents a potential target for pharmacological agents 
able to treat diverse pathological conditions such as cancer, chronic pain and Alzheimer’s disease.4 
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In the past ten years, massive efforts have been implemented in order to obtain potent MAGL 
inhibitors;5-10 however, almost all the compounds found showed irreversible inhibition properties.11 
In this context the reference inhibitors that have been used in the literature for most cellular and 
animal experiments are 4-nitrophenyl-4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-
carboxylate 1 (JZL184, Figure 1)8 and the benzyl(4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-
methylphenyl)carbamate 2 (CAY10499, Figure 1).5 As reported by Scholsburg and co-workers, the 
irreversible inhibition of MAGL, induced by repeated administration of 1, yielded cross-tolerance to 
CB1 agonists in mice.
12 Chronic MAGL inhibition also produced physical dependence, desensitized 
brain CB1 receptors and damaged endocannabinoid-dependent synaptic plasticity.
12 Genetic 
inactivation of MAGL or prolonged pharmacological blockage of MAGL by an irreversible inhibitor 
provokes the persistence of elevated 2-AG levels in the brain. This fact leads to a tolerance of the 
effects induced by MAGL inhibition. Moreover, responses to CB1 agonists were significantly reduced 
and there was an evident cross-tolerance when exogenous CB1 agonists were administered, resulting 
in a general CB1 desensitization. Furthermore, profound alterations to CB1 receptor expression and 
function in the brain were observed. Considering all these drawbacks associated to an irreversible 
MAGL inhibition, the need to discover selective and reversible MAGL inhibitors remains urgent. To 
our knowledge, the only compounds described as good reversible MAGL inhibitors are the naturally 
occurring terpenoids pristimerin and euphol (Figure 1).13 However, these two compounds act on a 
large number of secondary targets and this makes their use and study as MAGL inhibitors very 
difficult.14,15 Very recently, the reversible MAGL inhibitor benzo[d][1,3]dioxol-5-ylmethyl 6-
phenylhexanoate 3 (compound c21, Figure 1) was tested in vivo using the experimental allergic 
encephalomyelitis (EAE) mouse model, which is broadly studied as an animal model of human CNS 
demyelinating diseases, including multiple sclerosis and acute disseminated encephalomyelitis.16 
This molecule was able to ameliorate the clinical progression of the multiple sclerosis mouse model 
and, very importantly, the therapeutic effects were not accompanied by catalepsy or other motor 
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impairments that have been observed after the administration of irreversible MAGL inhibitors, thus 
supporting the hypothesis that reversible inhibitors could be profitably used in in vivo models.16  
We have recently reported a virtual screening study for the discovery of new reversible MAGL 
inhibitors. Among the tested compounds, (4-(4-chlorobenzoyl)piperidin-1-yl)(4-
methoxyphenyl)methanone 4 (CL6a, Figure 2) proved to be an interesting reversible MAGL inhibitor 
lead due to its inhibition activity (Ki = 8.6 µM and IC50 = 11.7 µM), the absence of stereocenters in 
its structure and its good synthetic accessibility.17 With the aim of identifying potent and selective 
MAGL inhibitors, chemical modifications guided by molecular modeling predictions of the probable 
binding poses were made to the structure of the initial compound 4 as a first step of our attempt to 
improve the inhibition potency of 4 on MAGL. The synthesis of new analogues of 4, their biological 
characterization on the isolated enzyme as well as their antiproliferative activities on a series of cancer 
cells are reported in this study. 
 
Figure 1. Structures of known MAGL inhibitors. 
 
RESULTS AND DISCUSSION 
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Design and Molecular Modeling. As shown in Figure 2, by using a plane that divides the piperidine 
ring we can observe that compound 4 is symmetrical, with the exception of the piperidine nitrogen 
atom and the different aryl substituents at the two opposite sides of the molecule (a chloro atom in 
position 4 of the phenyl ring of the ketone side and a methoxy group in the same position of the 
phenyl ring of the amidic portion). 
 
Figure 2. 2D analysis of compound 4. 
 
Before proceeding with the synthesis of 4 analogues, an extensive docking analysis was carried out 
in order to establish the binding disposition of this ligand. Figure S1 shows the clustering analysis of 
the docking results. This plot highlights the presence of two possible binding dispositions of the 
ligand, as there are two highly populated clusters of docking poses with very similar energy 
interaction scoring values. The most energetically favorable binding mode shows that the amidic C=O 
group of 4 forms two H-bonds with the nitrogen backbone of A51 and M123 and the 4-
methoxyphenyl fragment is directed towards an open cavity of the protein showing lipophilic 
interactions with L148, L213 and L241. The 4-chlorobenzoyl moiety is inserted into a small pocket 
of the protein and shows lipophilic interactions of the phenyl ring with Y194 and V270 (binding mode 
A of Figure 3). Figure 3B shows a representative docking pose of the second cluster which is more 
populated than the first one, but it shows a slightly lower energy interaction score. As expected, this 
binding disposition is symmetrical to the first one: the 4-chlorobenzoyl moiety of the 4 is directed 
towards the open cavity of the protein showing lipophilic interactions with L148, L213 and L241 and 
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forms two H-bonds with the nitrogen backbone of A51 and M123. With regards to the 4-
methoxybenzoyl fragment, it is inserted into the small pocket of the protein and the phenyl ring shows 
lipophilic interactions with Y194 and V270. 
 
Figure 3. Docking of compound 4 into hMAGL. (A) Binding mode A; (B) binding mode B. 
 
In order to identify which one is the preferred binding mode among the two proposed solutions by 
the docking analysis (see Figure 3), we planned to synthesize two analogues of compound 4 that are 
respectively able to adopt only one of these binding modes. In fact, biphenylic compounds 5 and 6 
(Table 1) were designed considering: a) the small volume of the pocket delimited by E53, R57, Y58, 
Y194, V270 and H272, and b) the open shape of the cavity on the opposite side of the binding site. 
These two compounds are characterized by the presence of a bulky biphenyl ring that we 
hypothesized could lie only in the open cavity of the binding site surrounded by hydrophobic residues 
L148, L213 and L241. As shown in Figure 4 and Figure S2, our hypothesis was confirmed by the 
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docking studies, since there was only one predicted binding disposition for each compound, with the 
biphenyl ring that was placed in the open cavity of the binding site. Due to this disposition, compound 
5 shows the binding mode A, with the C=O amidic group forming two H-bonds with the backbone 
N-H of A51 and M123. Conversely, compound 6 shows the binding mode B, with the ketone group 
that forms two H-bonds with the backbone nitrogen of A51 and M123. 
 
 
Figure 4. Docking results of compound 5 (A) and 6 (B) into hMAGL. 
 
The two compounds were thus synthesized and tested for their hMAGL inhibition activity together 
with the piperidine-1,4-diylbis((4-chlorophenyl)methanone) derivative (7a, Table 1), which was used 
as a reference compound, since it possesses the para-chloro substituted phenyl ring on both sides of 
the molecule, without the bulky biphenyl part that is present in the amidic portion of compound 5 or 
in the ketone moiety of compound 6. As shown in Table 1, in agreement with the docking results, 
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both binding modes are possible since both compounds show inhibition of MAGL activity. However, 
the binding mode B is the preferred one, since compound 6 shows a 5-fold higher activity (IC50 = 2.1 
µM) than that of compound 5 (IC50 = 9.9 µM). Subsequently, two derivatives of compound 4 were 
synthesized and tested for their hMAGL inhibition activity in order to inspect the role of the central 
scaffold (Table 1). Compound 8, which is characterized by the replacement of the two C=O groups 
with two methylene moieties, showed a complete loss of inhibition activity (IC50 greater than 100 
µM). Similar results were also obtained for compound 9, which possesses a central piperazine ring 
instead of piperidine, thus introducing a second amidic group that further rigidifies the structure by 
reducing the rotational freedom of the p-chlorobenzoyl portion. Both results supported the important 
role of the central piperidine ring bearing a carbonyl group in the opposite position to the amidic 
fragment for the establishment of an efficient interaction with the enzyme, thus confirming the key 
role played by the central scaffold of 4, which justifies the development of a series of analogues of 
this compound. 
Table 1. Structure and hMAGL activity of compounds 5, 6, 7a, 8 and 9. 
# Structure IC50 (µM) 
5 
 
9.9 ± 0.6 
6 
 
2.1 ± 0.4 
7a 
 
5.4 ± 0.1 
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> 100 
9 
 
> 100 
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Hence, once we identified the preferred binding mode of this class of compounds into hMAGL, we 
proceeded with the lead optimization of 4. As a first step in the development of this scaffold, we 
decided to improve the interaction of the compound inside the small pocket delimited by E53, R57, 
Y58, Y194, V270 and H272 while maintaining the rest of the molecule fixed. On this basis, we 
replaced the p-methoxyphenyl ring present in the amidic portion of the initial compound 4 with 
differently substituted aryl groups and kept the p-chlorobenzoyl unit fixed. Hence, we explored the 
ortho/meta/para effects generated by the presence in the amidic phenyl ring of halogen atoms (F, Cl, 
Br, I), methyl, trifluoromethyl, methoxy, trifluoromethoxy, hydroxy, amino and nitro substituents, by 
testing the inhibitory activities of the series of novel compounds reported in Table 2.  
Enzymatic experiments. The inhibitory effects of the newly synthesized compounds on human 
isoforms of MAGL by using 4-nitrophenylacetate substrate are reported in Table 2, together with 
those of the reference irreversible inhibitor 1 and of the recently reported reversible inhibitor 3. 
Considering the activity of compound 20 (IC50 = 6.5 µM), which possesses an unsubstituted phenyl 
ring, the introduction in all the three o/m/p positions of the aromatic ring of bromine and iodine 
(compounds 11a-c and 12a-c) determined an increase of the activity (IC50 values in the range 2.4-4.8 
µM). The presence of the other substituents generally led to a certain reduction of inhibition activity, 
which resulted to be either lower than that of reference compound 20 (IC50 values in the range 9.9-
57.3 µM) or comparable (IC50 = 5.4 µM for 7a, IC50 = 7.1 µM for 13c). It is worth noting that almost 
all the reported compounds show an activity that is similar or even better than that of the reference 
reversible inhibitor 3. 
 
Table 2. Structures and hMAGL inhibitory activities of the synthesized compounds. 
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Compounds R1 R2 R3 IC50 (µM) 
7a H H Cl 5.4 ± 0.7 
7b H Cl H 17.1 ± 0.1 
7c Cl H H 10.4 ± 0.5 
10a H H F 17.8 ± 0.9 
10b H F H 20.4 ± 0.1 
10c F H H 13.4 ± 0.6 
11a H H Br 2.4 ± 0.1 
11b H Br H 4.8 ± 0.4 
11c Br H H 4.0 ± 0.4 
12a H H I 4.4 ± 0.2 
12b H I H 4.3 ± 0.4 
12c I H H 2.4 ± 0.2 
13a H H CH3 11.8 ± 0.4 
13b H CH3 H 10.9 ± 0.8 
13c CH3 H H 7.1 ± 0.1 
14a H H CF3 29.8 ± 1.3 
14b H CF3 H 11.9 ± 0.4 
14c CF3 H H 26.3 ± 2.4 
4 H H OCH3 11.7 ± 2.2 
15b H OCH3 H 9.9 ± 1.7 
15c OCH3 H H 11.5 ± 0.3 
16a H H OCF3 26.6 ± 2.6 
16b H OCF3 H 16.3 ± 1.0 
16c OCF3 H H 17.3 ± 1.2 
17a H H OH 11.7 ± 1.7 
17b H OH H 0.84 ± 0.04 
17c OH H H 32.8 ± 4.3 
18a H H NH2 16.7 ± 1.7 
18b H NH2 H 57.3 ± 2.2 
18c NH2 H H 15.5 ± 1.9 
19a H H NO2 14.2 ± 0.3 
19b H NO2 H 24.9 ± 3.5 
19c NO2 H H 24.0 ± 0.4 
20 H H H 6.5 ± 0.1 
1  0.048 ± 0.005 
2  0.134 ± 0.015 
3  9.0 ± 1.5 
 
Among the 34 reported derivatives, the m-hydroxy-substituted derivative 17b showed a high 
inhibition activity (IC50 = 0.84 µM), about 14 fold more potent than the starting 4 lead compound. In 
order to better rationalize the activity of this compound, 17b was subjected to docking calculations, 
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together with its analogues 17a and 17c. Binding mode B of compound 17b resulted to be more 
energetically favorable than the other one (see Figure S3). The overall disposition of the molecule is 
comparable to that observed for compound 4, with the 4-chlorobenzoyl moiety that is directed 
towards the open cavity of the protein showing lipophilic interactions with L148, L213 and L241 and 
the formation of two H-bonds with the backbone nitrogen of A51 and M123 (see Figure 5). The m-
hydroxybenzoyl fragment is inserted into the small pocket of the protein and shows lipophilic 
interactions between its aryl ring and residues Y194 and V270. Furthermore, the m-hydroxyl 
participates to a highly energetic H-bond network with residues E53 and H272, where it behaves as 
a H-bond acceptor with H272 and as a H-bond donor with E53. It is interesting to note that, analyzing 
the main crystal structures of hMAGL18-21 and superimposing them with the hMAGL-17b complex, 
the hydroxyl group of the ligand replaces a structural water molecule that acts as a H-bond bridge 
between E53 and H272, thus supporting the high activity of this compound (see Figure S4). The 
replacement of the m-hydroxyl with the o- and p-hydroxyl group determined a marked decrease of 
the MAGL inhibition activity (see compounds 17c and 17a, respectively). As shown in Figure S5, 
the docking results suggested that for both compounds the shift of the hydroxyl group from the meta 
to para and ortho position determines the loss of the H-bonds with E53 and H272, without 
establishing any further interaction.  
 
Figure 5. Docking results of compound 17b into hMAGL. 
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The replacement of the m-hydroxy with the m-amine group led to a marked decrease of activity 
(compound 18b, IC50 = 57.3 µM). Due to the planar geometry of the aniline nitrogen atom and to the 
delocalization of its electron lone pair in the adjacent π-system, it is unlikely that this group is able to 
act as a H-bond acceptor, thus supporting the low activity of this compound. 
With the aim of evaluating the reversible or irreversible mechanism of inhibition, the effects of 
dilution and preincubation on the inhibitory ability of compound 17b and of reference compounds 2 
and 3 were evaluated. In the dilution experiments, if the compound is an irreversible inhibitor, then 
its inhibition potency should not drop upon dilution, whereas inhibition levels should be substantially 
reduced upon dilution in the presence of a reversible inhibitor. As shown in Figure 6, 17b showed 
reversible inhibition, since the inhibition produced by 20 µM of the compound was significantly 
higher compared with that observed with a 40X dilution, which appears similar to that produced by 
a 0.5 µM concentration of the compound. The same results were also obtained for compound 3, 
whereas compound 2 showed an irreversible inhibition since the inhibition produced by 4 µM of the 
compound was substantially unchanged upon a 40X dilution, which appears significantly higher to 
that produced by a 0.1 µM concentration of this compound.  
 
 
Figure 6. Dilution assay for compounds 17b, 3 and 2: the first two columns indicate the inhibition 
percentage of compounds at a concentration of 20 µM and 0.5 µM (17b), 40 µM and 1.0 µM (3) and 
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4 µM and 0.1 µM (2). The third column indicates the inhibition percentage of compounds after a 40X 
dilution (final concentration = 0.5 µM, 1.0 µM and 0.1 µM for compounds 17b, 3 and 2, respectively). 
 
In order to further support these results, the activity of 17b, 2 and 3 were tested at different 
preincubation times of the inhibitors with the enzyme. An irreversible inhibitor will increase its ability 
to block MAGL over gradually longer incubation times. On the contrary, unchanged IC50 values in 
these experiments support a reversible mechanism of action.22 As expected, compound 17b and 3 
showed a constant MAGL inhibition activity even after 60 min of preincubation, thus supporting a 
reversible mode of action (see Figure 7). As expected, instead, a time-dependent increase of potency 
was observed for reference compound 2, which further supports its already known irreversible 
inhibitor character.5 
 
 
Figure 7. IC50 (µM) values of 17b, 3 and 2 at different preincubation times with hMAGL (0 min and 
60 min). 
 
Once we confirmed the reversibility of the inhibitory action of compound 17b, we then evaluated its 
inhibition mode by measuring Michaelis–Menten kinetics. The dataset was plotted as substrate 
concentration versus enzyme activity and analyzed by applying the mixed-model inhibition fit of 
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GraphPad Prism 5.0. This model, beyond the Vmax and Km values, also calculates the α parameter, 
which can be useful for establishing the inhibition mechanism. Its value is greater than zero and 
determines the extent to which the binding process of the inhibitor changes the affinity of the enzyme 
for the substrate. If the inhibitor does not modify the binding of the substrate to the enzyme, α is equal 
to one and the mixed-model corresponds to a noncompetitive inhibition. When α is a very large value, 
the binding of the inhibitor prevents that of the substrate and the mixed-model corresponds to a 
competitive inhibition. Finally, when α is a very small value, the binding of the inhibitor increases 
the binding of the substrate to the enzyme, and the mixed-model corresponds to an uncompetitive 
model. Kinetic studies indicate for 17b a Ki value of 0.65 ± 0.05 µM and an α value greater than 
10000, thus suggesting a competitive binding for this compound (Figure 8). 
 
 
Figure 8. Michaelis–Menten plot for the determination of the Ki of compound 17b for hMAGL (Ki 
= 0.65 ± 0.05 µM, α >10000). 
 
As a further analysis, in order to explore the potential activity of these compounds for other 
hydrolases, the selectivity versus the analogue enzyme fatty acid amide hydrolase (FAAH) of some 
of the most promising inhibitors was evaluated. As shown in Table 4, all the tested compounds 
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showed MAGL selectivity. In particular, compound 17b displayed a MAGL selectivity greater than 
119-fold. 
 
Table 4. MAGL selectivity versus FAAH for the best compounds. 
Compd MAGL IC50 (µM) FAAH IC50 (µM) Selectivity Index 
11b 4.8 ± 0.4 > 100 > 21 
12c 2.4 ± 0.2 86.7 ± 5.1 36 
13c 7.1 ± 0.2 > 100 > 14 
17b 0.84 ± 0.04 > 100 > 119 
3 9.0 ± 1.5 27.7 ± 1.1 3 
 
Molecular dynamic simulation. In order to evaluate the reliability of the docking results and to carry 
out an analysis of the ligand–protein interaction, the hMAGL-17b complex was used as a starting 
structure for 51 ns of molecular dynamic (MD) simulation. As shown in Figure S6, the complex is 
stable during the simulations and the analysis of the root-mean-square deviation (rmsd) of all the 
heavy atoms from the X-ray structures highlights a stabilization of the rmsd value around 0.8 Å. With 
regard to the geometry of the compounds, analyzing the rmsd of the position of the ligand during the 
simulations with respect to the starting structure, it maintains its starting disposition with an rmsd 
value between 0.3 and 0.7 Å. With regard to the H-bond analysis (Table S1 in the Supporting 
Information), the interaction of the hydroxyl group with E53 and H272 appears to be very stable, 
similarly to the interaction with the nitrogen backbone of A51. Differently from what reported in the 
docking studies, the interaction with the backbone nitrogen of M123 is not highly conserved; 
however, this is due to a small shift of the ligand with the formation of a very stable H-bond between 
the hydroxyl group of S181 and the amidic oxygen of the compound (see Figure S7). 
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Antiproliferative assays. Compound 17b was also further tested in in vitro experiments for 
evaluating its antiproliferative activity against cancer cells. Compound 2 and 3 were used as reference 
compounds. Due to the potential role of MAGL as a therapeutic target in ovarian cancer,23 four human 
ovarian cancer cell lines (OVSAHO, OVCAR3, COV318 and CAOV3) were chosen and a western 
blot analysis was carried out in order to measure the overexpression of MAGL in these cells. As 
shown in Figure 9A, western blot analysis highlighted an overexpression of MAGL in OVCAR3 and 
CAOV3 compared to OVSAHO and COV318 cell lines. Compound 17b caused a considerable 
inhibition of cell viability, with IC50 values ranging from 31.5 to 43.9 μM in the OVCAR3 and 
CAOV3 cell lines (Table S2), whereas it proved to be remarkably less potent against ovarian cancer 
cells that do not overexpress MAGL, such as OVSAHO and COV318 cells. Furthermore, 17b proved 
to be completely inactive also against noncancerous human fibroblast lung cells (MRC5, Figure 9B). 
Differently, the covalent reference inhibitor 2 showed inhibition of cell viability in all the four ovarian 
cancer cell lines, with IC50 values ranging from 17.2 to 83.1 μM (Table S2). This behavior may be 
due to the lack of target-selectivity of this compound, thus we cannot exclude that the involvement 
of different targets could contribute to its antiproliferative potential. Surprisingly, the known MAGL 
inhibitor 3 displayed a substantial inactivity against all the tested cell lines. Overall, these data suggest 
that the reversible inhibition of MAGL operated by the herein reported class of compounds may be a 
possible profitable alternative to the irreversible inhibition treatment.  
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Figure 9. A) Western blot analysis of MAGL expression in ovarian cancer cell lines. Vinculin was 
utilized to normalize the amount of total loaded proteins. B) Cell growth inhibitory activities (IC50) 
of compounds 2, 17b and 3. 
 
Chemistry. Benzoyl piperidine derivatives 4, 7a-c, 10a-c, 11a-c, 12a-c, 13a-c, 14a-c, 15b-c, 16a-c, 
19a-c and 20 were synthesized by an amide coupling between properly substituted benzoic acids and 
4-(4-chlorobenzoyl)piperidine 21 in the presence of the condensing agent HATU and DIPEA as the 
base in dry N,N-dimethylformamide as the solvent, as previously reported for compound 4.17 
Hydroxy-substituted derivatives 17a-c were obtained after BBr3-promoted deprotection of the 
corresponding methoxylated precursors 4, 15b-c. A particular case was the ortho-amino substituted 
compound 18c which, unlike its analogues para- and meta-NH2-bearing compounds 18a-b (see 
Scheme 2), was directly obtained from condensation of 4-(4-chlorobenzoyl)piperidine with 
anthranilic acid (Scheme 1), since the protection of the amino moiety with tert-butyloxycarbonyl 
group, similarly adopted for the para- and meta-analogues, needed very long reaction times with the 
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simultaneous formation of many side-products, therefore the direct condensation was preferred, 
although this caused a decrease in the reaction yield. 
 
Scheme 1. Synthesis of benzoyl-piperidine derivatives.a 
aReagents and conditions: (a) properly substituted benzoic acid (1 eq), HATU (1.05 eq), DIPEA (4 
eq), dry DMF, RT, 6-8 h; (b) 1M BBr3, dry CH2Cl2, −78 to 0 °C, then RT, 1-2 h. 
 
As anticipated in the previous discussion, the synthesis of amino-substituted compounds 18a-b 
started with the formation of the methyl esters 24 and 25 from the corresponding amino-benzoic acids 
22 and 23 by refluxing them in MeOH in the presence of SOCl2 (Scheme 2). Boc-protection of the 
amino groups with di-tert-butyl dicarbonate in the presence of triethylamine in THF gave compounds 
26 and 27, which were then hydrolyzed to give Boc-protected benzoic acids 28 and 29 ready to be 
condensed with piperidine 21. The amino groups of the intermediate amides 30 and 31 were finally 
deprotected by reaction with trifluoroacetic acid in DCM to obtain compounds 18a and 18b in good 
yields. 
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Scheme 2. Synthesis of meta and para-amino-substituted benzoyl-piperidine derivatives 18a-b.a 
aReagents and conditions: a) MeOH, SOCl2 (2.5 eq), reflux, 3 h; (b) (Boc)2O (2 eq), Et3N (2 eq), dry 
THF, RT, 24 h; (c) aq. 2N LiOH (6 eq), THF/MeOH 1:1 v/v, RT, overnight; (d) (4-
chlorophenyl)(piperidin-4-yl)methanone 21 (1 eq), HATU (1.05 eq), DIPEA (4 eq), dry DMF, RT, 
3-4 h; (e) CF3COOH, dry DCM, 0 °C to RT, 3-5 h. 
 
The synthetic approaches for the synthesis of the biphenyl derivatives 5 and 6 are reported in Schemes 
3 and 4. For the synthesis of compound 5, [1,1'-biphenyl]-4-carboxylic acid 35 was obtained after a 
sequence of reactions starting from 4-bromobenzoic acid 32, consisting in a Fischer esterification to 
obtain the methyl ester 33, followed by a palladium-catalyzed cross-coupling reaction to replace the 
bromine atom with a phenyl ring. This step required anhydrous conditions to prevent the hydrolysis 
of the methyl ester group under prolonged heating in the presence of alkaline solutions, since the 
isolation and purification of the biphenyl methyl ester was preferred. Finally, hydrolysis of the methyl 
ester gave compound 35 which was condensed with 4-(4-chlorobenzoyl)piperidine 21 in the presence 
of HATU and DIPEA to yield the desired compound. The synthesis of compound 6 started with the 
protection of piperidine 21, then a cross-coupling reaction adopting the Fu-type conditions, which are 
suitable for the coupling of aryl chlorides with the appropriate phenylboronic acid, using the catalytic 
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system containing Pd2(dba)3 and tricyclohexylphosphine, and cesium carbonate as the base, gave 
compound 37. TFA-promoted deprotection of the piperdine N-atom gave compound 38, which was 
reacted with 4-chlorobenzoic acid in the same conditions adopted for all the amidic condensation of 
this class of compounds to produce compound 6 in high yields. 
 
Scheme 3. Synthesis of biphenyl derivative 5.a 
aReagents and conditions: (a) MeOH, H2SO4, reflux, overnight; (b) PhB(OH)2 (2 equiv), Pd(OAc)2 
(0.03 eq), PPh3 (0.15 eq), K2CO3 (1.5 eq), toluene, 100 °C, 18 h; (c) aq. 2N LiOH (6 eq), THF/MeOH 
1:1 v/v, RT, 20 h; (d) (4-chlorophenyl)(piperidin-4-yl)methanone 21 (1 eq), HATU (1.05 eq), DIPEA 
(4 eq), dry DMF, RT, 3 h. 
 
Scheme 4. Synthesis of biphenyl derivative 6.a 
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aReagents and conditions: (a) (Boc)2O (1.2 eq), Et3N (2 eq), dry THF, RT, 2 h; (b) PhB(OH)2 (1.6 
equiv), Pd2(dba)3 (0.032 eq), Cy3P 20% toluene (0.08 eq), Cs2CO3 (1.7 eq), dioxane, 100 °C, 
overnight; (c) CF3COOH, dry DCM, 0 °C to RT, 2 h; (d) 4-chlorobenzoic acid (1 eq), HATU (1.05 
eq), DIPEA (4 eq), dry DMF, RT, 6 h. 
 
The synthesis of compounds 8 and 9 is reported in Scheme 5 and for both derivatives a one-pot 
procedure gave the desired products. Derivative 8 was obtained by alkylation of 4-(4-
chlorobenzyl)piperidine hydrochloride 39 with 4-methoxybenzyl chloride 40 using potassium 
carbonate as the base. Differently, the amidic condensation between 1-(4-chlorobenzoyl)piperazine 
41 and 4-methoxybenzoic acid 42 under the same conditions previously described for the synthesis 
of other compounds (Schemes 1-4) gave derivative 9. 
 
Scheme 5. Synthesis of compounds 8 and 9.a 
aReagents and conditions: (a) an. K2CO3 (3 eq.), dry DMF, RT, overnight; (b) HATU (1.05 eq), 
DIPEA (4 eq), dry DMF, RT, 3 h. 
 
For the synthesis of compound 43 (see Conclusions section), the synthetic scheme described for the 
preparation of biphenylic piperidine 38 (Scheme 4) was adopted, then piperidine 38 was submitted to 
a condensation with 3-methoxybenzoic acid to get amide 44, followed by deprotection of the methoxy 
group with boron tribromide, to obtain the final compound 43 (Scheme 6). 
22 
 
 
Scheme 6. Synthesis of compound 43.a 
aReagents and conditions: (a) (Boc)2O (1.2 eq), Et3N (2 eq), dry THF, RT, 2 h; (b) PhB(OH)2 (1.6 
equiv), Pd2(dba)3 (0.032 eq), Cy3P 20% toluene (0.08 eq), Cs2CO3 (1.7 eq), dioxane, 100 °C, 
overnight; (c) CF3COOH, dry DCM, 0 °C to RT, 2 h; (d) 3-methoxybenzoic acid (1 eq), HATU (1.05 
eq), DIPEA (4 eq), dry DMF, RT, 4 h; (e) 1M BBr3, dry CH2Cl2, −78 to 0 °C, then RT, 1 h. 
 
A detailed analysis of 1H and 13C-NMR spectra of some (1-benzoylpiperidin-4-yl)(4-
chlorophenyl)methanone derivatives revealed the presence of two rotational conformers generated by 
the rotation of the bond between the variously substituted phenyl ring and the amidic carbonyl group. 
The splitting of 1H and 13C-NMR signals was observed for ortho-substituted compounds, since the 
presence of bulky groups in this position such as Cl (7c), Br (11c), I (12c), CF3 (14c), CH3 (13c), 
OCH3 (15c), and OCF3 (16c) led to the presence of two rotational conformers. Conversely when the 
substituents are either absent or are present in meta or para positions the rotation is free at room 
temperature and a unique conformer is observed by NMR analysis. In the case of compounds 17c and 
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18c, the presence of ortho-OH (17c) or ortho-NH2 (18c) groups allows the formation of an 
intramolecular H-bond between the hydrogen atom of hydroxyl or amino group and the amide C=O 
oxygen atom, thus inducing a stabilization of only one conformer. Surprisingly, for ortho-fluoro 
derivative 10c no splitting of signals was observed, despite the non-negligible steric hindrance of the 
halogen atom. This observation may be explained considering the partial negative charge of both the 
fluorine atom and the carbonyl oxygen atom, which cause a charge repulsion leading to the 
stabilization of the conformer where these two atoms maximize their distance. Similarly, the single 
conformer observed for the ortho-nitro derivative 19c may have the nitro group and the carbonyl 
oxygen atom distant, due to the repulsion between the partially negatively charged oxygen of the 
amide C=O and the negatively charged oxygens of the NO2 group, causing the block of the rotation 
which leads to the presence of a single conformer. The presence of conformer was verified for a 
representative compound, (4-(4-chlorobenzoyl)piperidin-1-yl)(2-iodophenyl)methanone 12c, by 
acquiring 1H-NMR spectrum at high temperature (80 °C) in a suitable solvent (DMSO-d6), in order 
to overcome the energetic rotational barrier for the different conformers and thus collapse the splitting 
of signals. As shown in Figures S8-S10, the high temperature increased the interconversion rate 
between the two rotamers and the spectrum revealed a collapse of the signals of the two conformers, 
which is particularly evident in the aromatic region of the spectrum. 
CONCLUSIONS 
In summary, molecular modeling predictions of the probable binding pose guided chemical 
modifications of the structure of the initial compound 4 as a first attempt to improve the inhibition 
potency of this compound on hMAGL. The first part of the structural optimization of 4 led to the 
identification of compound 17b, which displayed remarkably high MAGL inhibition activity, 
selectivity for MAGL over FAAH, reversible interaction properties and antiproliferative activity in 
cancer cells. Therefore, to the best of our knowledge 17b can now be considered as one of the most 
active reversible MAGL inhibitors ever reported so far in literature. Finally, the m-hydroxyl 
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substituent of this compound replaces a structural water molecule present in the main crystal 
structures of hMAGL.18-21 Considering that almost all the known MAGL inhibitors show H-bond 
interactions only in the proximity of the oxyanion hole, constituted by the backbone NH groups of 
A51 and M123, the possibility of replacing a water molecule by forming profitable H-bonds also with 
E53 and H272 residues could provide a new key anchoring point for the development of new MAGL 
inhibitors. As a further attempt to improve the MAGL inhibition activity of the reported compounds, 
the replacement of the p-chlorophenyl group of compound 17b with fragments that are characterized 
by different size and interaction points is currently underway. In the present paper we have modified 
only the amidic phenyl portion of the scaffold with the insertion of simple and small groups as a first-
stage optimization study. It is our purpose now to carry out further modifications of the structure of 
the best compound 17b, with the aim of obtaining derivatives that are characterized by an improved 
MAGL inhibition activity. As a preview of our future optimization work, we have observed that the 
replacement of the p-chlorophenyl ring with a biphenyl ring (compound 6) leads to about a two-fold 
increase of activity (compared to compound 7a). Therefore, as a preliminary attempt to improve the 
activity of compound 17b, we synthesized and tested the (4-([1,1'-biphenyl]-4-carbonyl)piperidin-1-
yl)(3-hydroxyphenyl)methanone derivative (compound 43, Scheme 6). As shown in Figure S13, in 
an agreement with the herein reported data, adding a second phenyl ring in compound 43 led to a 
two-fold increase of activity with respect to 17b (IC50 = 0.46 ± 0.02 µM), thus confirming the 
promising possibilities of further improving the inhibition activity of the best derivative of this series 
of compounds by modifying the p-chlorophenyl region of the molecule. 
EXPERIMENTAL SECTION 
Pan Assay Interference Compounds (PAINS) analysis. 
The herein reported class of compounds could act as artifacts and promiscuous bioactive molecules. 
Therefore, a PAINS analysis for the most active compound (17b) was carried out in order to analyze 
and exclude this possibility. 
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PAINS substructural features screening. Baell and Holloway published an interesting paper on the 
analysis of frequent hitters from screening assays.24 This report described a number of substructural 
features which could help to identify compounds that appear as PAINS in many biochemical high 
throughput screens. In the supplementary information they provided the corresponding filters that 
have been included in the Filter-itTM software. Compound 17b was thus filtered by using this program 
and as a result it was recognized as no PAIN molecule because it did not possess any of the 
substructural features shared by the most common PAINS. 
Interference analysis. Some PAINS are associated with color that could interfere photometrically 
with the assay. As reported in the part of MAGL inhibition assay of the Experimental Section, in 
order to avoid this possibility for each compound concentration a blank analysis was carried out, and 
the final absorbance values resulted from the subtraction of the absorbance determined by the 
presence of all the components except the enzyme in the same conditions. Furthermore, a specific 
analysis for compound 17b was carried out. The 4-nitrophenylacetate (4-NPA) to 4-nitrophenol (4-
NP) conversion curve was prepared at 100 µM total concentration of 4-NPA+4-NP in the presence 
and absence of 17b at a concentration of 200 µM. As shown in the Figure S11, the two resulting 
curves were superimposable. As a positive control, we analyzed in the same conditions the effects of 
quercetin at 200 µM, that resulted in a shifted curve. Finally, we analyzed the results in the first part 
of the plot, in the 100-80 µM concentration range of 4- NPA (corresponding to 0-20% conversion of 
4-NAP to 4-NP). As shown in Figure S11 the two straight lines measured in the presence and absence 
of 17b were almost identical, differently from what observed for quercetin, that produced a shifted 
line, thus suggesting that 17b did not interfere with the reading at 405 nm in the enzymatic assay. 
Aggregation analysis. All the enzymatic assays were carried out in the presence of bovine serum 
albumin (BSA) 0.1 mg/ml. However, in order to further verify the possible formation of aggregates, 
the MAGL inhibition activity of compound 17b was also tested in the presence of 0.01% (v/v) Triton 
X-100 as detergent. With respect to the IC50 value obtained in the presence of BSA (IC50 = 0.84 ± 
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0.04 µM), a similar result was obtained (IC50 = 0.76 ± 0.02 µM) in the presence of Triton X-100, 
supporting the notion that the ligand is operating as a monomer rather than an aggregate.25 
Thiol reactive analysis. As reported by Walters and co-workers,26 promiscuous enzymatic inhibition 
could be due in some cases to covalent reaction with cysteines on multiple proteins. MAGL inhibition 
activity of compound 17b was also tested in the presence of the thiol-containing agent 1,4-dithio-DL-
threitol (DTT).7 As shown in Figure S12, the MAGL-IC50 value of compound 17b was not influenced 
by the presence of DTT, as it showed a IC50 = 0.80 ± 0.05 µM when assayed with 100 M DTT, thus 
excluding the interaction of this compound with the cysteine residues of the MAGL enzyme. 
Selectivity testing and orthogonal assay. As reported by Dahlin and Walters27 the selective activity 
of a compound and the measurement of the activity against the target by using a different readout 
method are two other steps that contribute to elucidate the PAINS properties. As reported in Table 4 
we measured the activity of compound 17b against FAAH and the results highlighted a MAGL 
selectivity greater than 119-fold. Furthermore, very recently Saccomanni and co-workers reported the 
development of an HPLC/UV assay for the evaluation of MAGL inhibitors.28 Therefore, the activity 
of compound 17b against MAGL was also tested by using this method. An aliquot of stock solutions 
of hMAGL was diluted 1:125 with Tris buffer (pH = 7.2; 10 mM, containing 1.0 mM EDTA) to 
obtain the working solutions of hMAGL at 1.6 ng/µl. The stock and working solutions were stored at 
−20 °C. In a 0.5 ml spin tube containing 75 µl of Tris buffer (pH = 7.2; 10 mM containing 1.0 mM 
EDTA), 5 µl of working solution hMAGL (8 ng), and 5 µl inhibitor (or solvent as control) were 
added. Samples were pre-incubated for 30 min at 37 °C and then 5 µl of a solution of 4-NPA in 
absolute ethanol (4.25 mM) were added. Samples were incubated for 10 min at 37 °C. The enzymatic 
reaction was stopped by cooling in an ice bath for 10 min and then 20 µl of the reaction mixture were 
taken and analyzed by HPLC. Thermo Finnigan HPLC system was used to quantify 4-NP formed 
after enzymatic hydrolysis of 4-NPA by using a UV detector at operation wavelength of 315 nm. 
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Separation of compounds was carried out on to reverse-phase column (150 mm × 4.6 mm; 5 µm). 
The mobile phase, delivered at a flow rate of 1.0 ml/min and consisted of methanol and ammonium 
acetate buffer (pH 4.0; 10 mM) (53:47, v/v). The sample injection volume was 20 µl. The HPLC 
system consists of a Thermo Finnigan SpectraSystem SN4000 system controller, coupled with P2000 
pump, a SCM1000 degasser and a UV2000 UV detector at operation wavelength of 315 nm. Data 
were monitored and analyzed using ChromQuest software (Thermo Finnigan, Waltham, MA, USA). 
Separation of compounds was carried out at r.t. on to reverse-phase Chrompack HPLC column SS 
150 mm × 4.6 mm; 5 m, with ChromSep guard column intersil 5 ODS-3 (Varian, Palo Alto 
California).  
By using this assay method, compound 17b showed an IC50 against MAGL of 1.1 ± 0.3 µM, thus 
confirming the inhibition activity measured by the colorimetric assay. 
General Procedures and Materials.  
All solvents and chemicals were used as purchased without further purification. Chromatographic 
separations were performed on silica gel columns by flash chromatography (Kieselgel 40, 
0.040−0.063 mm; Merck). Reactions were followed by thin layer chromatography (TLC) on Merck 
aluminum silica gel (60 F254) sheets that were visualized under a UV lamp. Evaporation was 
performed in vacuo (rotating evaporator). Sodium sulfate was always used as the drying agent. Proton 
(1H) and carbon (13C) NMR spectra were obtained with a Bruker Avance III 400 MHz spectrometer 
using the indicated deuterated solvents. Chemical shifts are given in parts per million (ppm) (δ relative 
to residual solvent peak for 1H and 13C). 1H-NMR spectra are reported in this order: multiplicity and 
number of protons. Standard abbreviation indicating the multiplicity were used as follows: s = singlet, 
d = doublet, dd = doublet of doublets, t = triplet, tt = triplet of triplets, dt = doublet of triplets, td = 
triplet of doublets, q = quartet, m = multiplet, bm = broad multiplet and bs = broad signal. HPLC 
analysis: all target compounds (i.e., assessed in biological assays) were ≥ 95% pure by HPLC, 
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confirmed via UV detection (λ = 254 nm). Analytical reversed-phase HPLC was conducted using a 
Kinetex EVO C18 column (5 μm, 150 × 4.6 mm, Phenomenex, Inc.); eluent A, water; eluent B, 
CH3CN; after 5 min. at 25% B, a gradient was formed from 25% to 75% of B in 5 min and held at 
75% of B for 10 min; flow rate was 1 mL/min. HPLC analyses were performed at 254 nm, with the 
exception of compound 8 which was analyzed at 226 nm (UV-visible spectrum and superimposition 
of HPLC chromatograms at 254 e 226 nm of compound 8 are reported in the Supporting Information 
section). Yields refer to isolated and purified products derived from non-optimized procedures. 
Compounds 1 and 2 were purchased from Cayman Chemical and 3 was synthesized as previously 
reported.16 Compound 4 was characterized as previously reported.17 
General procedure for the synthesis of benzoylpiperidines 5, 6, 7a-c, 10a-c, 11a-c, 12a-c, 13a-c, 
14a-c, 15b-c, 16a-c, 18c, 19a-c, 20, 30, 31, 44 and benzoylpiperazine 9. HATU (1.05 equiv) was 
added to a solution of the appropriate benzoic acid (0.447 mmol, 1 equiv) in dry DMF (2.1 mL), then 
DIPEA (0.31 mL, 4 equiv) was added dropwise. The resulting mixture was stirred at room 
temperature for 30 min and then 4-(4-chlorobenzoyl)piperidine 21 (100 mg, 1 equiv) or [1,1'-
biphenyl]-4-yl(piperidin-4-yl)methanone 38 (for compounds 6 and 44), or 1-(4-
chlorobenzoyl)piperazine 41 (for compound 9) was added and left under stirring at room temperature 
until consumption of starting material (TLC). After this time, DMF was evaporated under reduced 
pressure and the residue was diluted with water and extracted with EtOAc. The organic layer was 
washed sequentially with water, saturated brine, dried over Na2SO4 and the solvent was removed 
under reduced pressure. The residue was purified with a flash column chromatography (silica gel, 
appropriate mixture of n-hexane/ethyl acetate) and pure fractions containing the desired compound 
were evaporated to dryness affording the amides. 
Synthesis of 4-(4-chlorobenzyl)-1-(4-methoxybenzyl)piperidine (8). A solution of 4-(4-
chlorobenzyl)piperidine 39 (0.812 mmol, 1 eq) in 6.8 mL of DMF was treated with K2CO3 (3 eq) and 
4-methoxybenzyl chloride 40 (1.1 eq) and the reaction mixture was stirred at room temperature 
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overnight. The mixture was diluted with water and extracted into ethyl acetate. The organic extracts 
were washed successively with water and brine, and the organic solvent was removed under vacuum 
on a rotary evaporator. Crude product was purified by flash chromatography over silica gel. Elution 
with n-hexane/EtOAc (6:4) afforded the desired compound as a white solid (yield 53%). 1H-NMR 
(CDCl3) δ (ppm): 1.27-1.37 (m, 2H), 1.41-1.52 (m, 1H), 1.54-1.62 (m, 2H), 1.83-1.94 (m, 2H), 2.49 
(d, 2H, J = 7.0 Hz), 2.83-2.89 (m, 2H), 3.44 (s, 2H), 3.79 (s, 3H), 6.84 (AA’XX’, 2H, JAX = 8.7 Hz, 
JAA’/XX’ = 2.5 Hz), 7.04 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ = 2.2 Hz), 7.19-7.24 (m, 4H). 13C-NMR 
(CDCl3) δ (ppm): 32.18 (2C), 38.01, 42.64, 53.71 (2C), 55.38, 62.87, 113.66 (4C), 128.38, 130.55 
(4C), 131.64, 139.33, 158.81. HPLC analysis: retention time = 11.718 min; peak area, 99% (226 nm). 
Procedure for the synthesis of O-deprotected benzoylpiperidines 17a-c and 43. A solution of pure 
amides 4, 15b-c or 44 (0.23 mmol) in anhydrous CH2Cl2 (2.7 mL) was cooled to −78 °C and treated 
dropwise with a 1.0 M solution of BBr3 in CH2Cl2 (0.73 mL) under argon. The mixture was left under 
stirring at the same temperature for 5 min and then at 0 °C for 1 h and finally at RT until starting 
material was consumed (TLC). The mixture was then diluted with water and extracted with ethyl 
acetate. The organic phase was washed with brine, dried and concentrated. The crude product was 
purified by flash chromatography over silica gel. Elution with n-hexane/EtOAc (6:4 to 4:6) afforded 
the desired compounds. 
Procedure of deprotection for the synthesis of compounds 18a-b and 38. Compounds 30-31 or 37 
(0.135 mmol) were dissolved in CH2Cl2 (0.60 mL), cooled to 0 °C, treated with trifluoroacetic acid 
(0.18 mL) and stirred at rt until consumption of starting material (TLC). The mixture was concentrated 
to dryness under reduced pressure, diluted with EtOAc and washed with 1M solution NaHCO3, then 
the organic layer was dried over Na2SO4 and concentrated. The crude product was purified by flash 
chromatography over silica gel. Elution with n-hexane/EtOAc (3:7 to 4:6) or CHCl3/MeOH 85:15 
gave the title compounds. 
Procedure for the synthesis of methyl amino-benzoates 24 and 25. A solution of the appropriate 
commercially available aminobenzoic acids 22 or 23 (1.0 g, 1 equiv) in MeOH (20 mL) was cooled 
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to 0 °C followed by a dropwise addition of thionyl chloride (1.3 mL, 2.5 equiv). The mixture was 
refluxed for 3 h. After cooling to rt, evaporation of the solvent and neutralization by addition of a 
saturated aqueous NaHCO3 solution, the mixture was extracted with EtOAc and the combined organic 
layers were dried over Na2SO4 and concentrated. Purification by flash chromatography over silica gel 
and elution with n-hexane/EtOAc (7:3) afforded the title compounds. 
Procedure for the synthesis of methyl (tert-butoxycarbonyl)amino benzoates 26-27 and tert-
butyl 4-(4-chlorobenzoyl)piperidine-1-carboxylate 36. To a solution of compounds 24-25 or 21 
(0.1 g, 1 equiv) in dry THF (1.7 mL) and Et3N (2 equiv), (Boc)2O (2 equiv for 26 and 27, 1.2 equiv 
for 36) was added and the reaction was stirred at room temperature until disappearance of starting 
material (TLC). The solvent was evaporated in vacuo and the residue was dissolved in EtOAc, washed 
with 1M NaHCO3, water and brine. Then the organic layer was dried over Na2SO4 and concentrated. 
The crude product was purified by flash chromatography over silica gel. Elution with n-
hexane/EtOAc (95:5 to 8:2) afforded the desired compounds. 
Procedure for the synthesis of (tert-butoxycarbonyl)amino benzoic acids 28-29 and [1,1'-
biphenyl]-4-carboxylic acid 35. Methyl esters 26-27 or 34 (0.1 g) were dissolved in a 1:1 v/v mixture 
of THF/methanol (4 mL) and treated with 1.2 mL of 2N aqueous solution of LiOH. The reaction was 
stirred overnight, then the solvents were evaporated, and the residue was treated with 1 N aqueous 
HCl and extracted with EtOAc. The organic phase was dried and evaporated to afford the pure desired 
carboxylic acid derivatives. 
Procedure for the synthesis of methyl 4-bromobenzoate (33). 4-Bromobenzoic acid 32 (250 mg) 
was dissolved in MeOH until complete dissolution (20 mL), then conc. H2SO4 (cat.) was added 
dropwise and the mixture was refluxed overnight. After being cooled to rt, the solvent was evaporated 
in vacuo and the residue was dissolved in EtOAc, washed with 1M NaHCO3, then the organic layer 
was dried over Na2SO4 and concentrated. Pure 33 was obtained as a crystalline light-yellow solid 
(1.13 mmol, 92% yield) and it was used in the next step without any further purification. 
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Procedure for the synthesis of methyl [1,1'-biphenyl]-4-carboxylate (34). A solution of Pd(OAc)2 
(0.03 equiv) and triphenylphosphine (0.15 equiv) in toluene (9.0 mL) was stirred at rt under argon for 
10 min. After that period, the bromo-aryl precursor 33 (0.93 mmol, 1 equiv), K2CO3 (1.5 equiv), and 
phenylboronic acid (2 equiv) were sequentially added. The resulting mixture was heated at 100 °C in 
a sealed vial under argon overnight. After being cooled to rt, the mixture was diluted with water and 
extracted with EtOAc. The combined organic phase was dried and concentrated. The crude product 
was purified by flash chromatography over silica gel. Elution with n-hexane with 1% EtOAc afforded 
34 as a white solid (0.779 mmol, 84% yield). 
Procedure for the synthesis of tert-butyl 4-([1,1'-biphenyl]-4-carbonyl)piperidine-1-carboxylate 
(37). A solution of 36 (0.182 g, 0.562 mmol, 1 equiv) in anhydrous dioxane (1.7 mL) was sequentially 
treated, under nitrogen, with cesium carbonate (1.7 equiv), phenylboronic acid (1.6 equiv), Pd2(dba)3 
(0.032 equiv), and a 20% solution of tricyclohexylphosphine in toluene (0.08 equiv). The reaction 
was heated at 100 °C in a sealed vial under argon overnight. The reaction mixture was then cooled to 
rt, diluted with EtOAc, and filtered through a Celite pad. The organic filtrate was concentrated under 
vacuum, and the crude product was purified by flash chromatography (n-hexane/EtOAc 9:1) to yield 
pure 37 (0.535 mmol, 95% yield). 
(1-([1,1'-Biphenyl]-4-carbonyl)piperidin-4-yl)(4-chlorophenyl)methanone (5). Yellow solid; 
yield 67% from 21 and 35; 1H-NMR (CDCl3) δ (ppm): 1.78-2.07 (m, 4H), 3.00-3.26 (bm, 2H), 3.47-
3.56 (m, 1H), 3.87-4.07 (bm, 1H), 4.60-4.80 (bm, 1H), 7.38 (tt, 1H, J = 7.3, 1.6 Hz), 7.43-7.52 (m, 
6H), 7.57-7.62 (m, 2H), 7.63 (AA’XX’, 2H, JAX = 8.5 Hz, JAA’/XX’ = 1.9 Hz), 7.90 (AA’XX’, 2H, JAX 
= 8.8 Hz, JAA’/XX’ = 2.2 Hz). 
13C-NMR (CDCl3) δ (ppm): 28.73 (2C), 43.46, 127.27 (2C), 127.34 (2C), 
127.61 (2C), 127.91, 129.01 (2C), 129.29 (2C), 129.83 (2C), 134.08, 134.78, 139.90, 140.35, 142.76, 
170.45, 200.53. HPLC analysis: retention time = 13.758 min; peak area, 99% (254 nm). 
(4-([1,1'-Biphenyl]-4-carbonyl)piperidin-1-yl)(4-chlorophenyl)methanone (6). Light-yellow 
solid; yield 84% from 38 and 4-chlorobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.76-2.15 (m, 4H), 
3.00-3.28 (bm, 2H), 3.54-3.63 (m, 1H), 3.76-3.95 (bm, 1H), 4.58-4.78 (bm, 1H), 7.36-7.44 (m, 5H), 
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7.45-7.51 (m, 2H), 7.61-7.65 (m, 2H), 7.71 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 1.9 Hz), 8.03 
(AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 1.9 Hz). 13C-NMR (CDCl3) δ (ppm): 28.75 (2C), 43.44, 127.37 
(3C), 127.59 (2C), 128.48, 128.57 (2C), 128.92 (2C), 129.00 (2C), 129.12, 134.35, 134.42, 135.87, 
139.79, 146.18, 169.52, 201.21. HPLC analysis: retention time = 13.747 min; peak area, 97% (254 
nm). 
Piperidine-1,4-diylbis((4-chlorophenyl)methanone) (7a). White solid; yield 60% from 21 and 4-
chlorobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.72-2.05 (m, 4H), 3.00-3.20 (bm, 2H), 3.45-3.54 (m, 
1H), 3.72-3.96 (bm, 1H), 4.53-4.72 (bm, 1H), 7.34-7.41 (m, 4H), 7.46 (AA’XX’, 2H, JAX = 8.8 Hz, 
JAA’/XX’ = 2.2 Hz), 7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz). 13C-NMR (CDCl3) δ (ppm): 
28.65 (2C), 43.31, 128.57 (2C), 128.93 (2C), 129.31 (2C), 129.80 (2C), 134.03, 134.37, 135.93, 
139.96, 169.52, 200.40. HPLC analysis: retention time = 13.001 min; peak area, 98% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-chlorophenyl)methanone (7b). Light-yellow solid; yield 
68% from 21 and 3-chlorobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.73-2.09 (m, 4H), 2.98-3.23 
(bm, 2H), 3.45-3.55 (m, 1H), 3.74-3.91 (bm, 1H), 4.57-4.73 (bm, 1H), 7.29 (dt, 1H, J = 7.4, 1.5 Hz), 
7.35 (t, 1H, J = 8.0 Hz), 7.38-7.41 (m, 2H), 7.46 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.89 
(AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz). 13C-NMR (CDCl3) δ (ppm): 28.60 (2C), 43.24, 125.03, 
127.15, 129.27 (2C), 129.78 (2C), 129.93, 130.03, 133.97, 134.71, 137.72, 139.91, 168.93, 200.35. 
HPLC analysis: retention time = 12.961 min; peak area, 99% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-chlorophenyl)methanone (7c). Light-yellow solid; yield 
58% from 21 and 2-chlorobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.65-2.04 (m, 4H), 3.02-3.28 (m, 
2H), 3.40-3.60 (m, 2H), 4.75 (tt, 1H, J = 10.9, 4.0 Hz), 7.30-7.35 (m, 3H), 7.37-7.43 (m, 1H), 7.43-
7.48 (m, 2H), 7.86-7.90 (m, 2H). 13C-NMR (CDCl3; asterisk denotes isomer peaks) δ (ppm): 28.41, 
28.59, 28.66*, 41.01, 41.16*, 43.18, 43.38*, 45.87, 46.57*, 127.21*, 127.41, 127.67*, 127.84, 
129.24*, 129.27, 129.69*, 129.78 (4C), 129.86*, 130.21*, 130.32, 130.37, 130.53*, 134.01, 134.06*, 
135.97*, 136.08, 139.80*, 139.90, 166.90*, 167.04, 200.33*, 200.45. HPLC analysis: retention time 
= 12.699 min; peak area, 99% (254 nm). 
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(4-(4-Chlorobenzoyl)piperazin-1-yl)(4-methoxyphenyl)methanone (9). White solid; yield 61% 
from 41 and 4-methoxybenzoic acid 42; 1H-NMR (CDCl3) δ (ppm): 3.43-3.78 (bm, 8H), 3.84 (s, 3H), 
6.90-6.95 (m, 2H), 7.34-7.44 (bm, 6H). 13C-NMR (CDCl3) δ (ppm): 55.52, 114.04 (2C), 126.99, 
128.78 (2C), 129.08 (2C), 129.39 (2C), 133.55, 136.42, 161.31, 169.75, 170.87. HPLC analysis: 
retention time = 10.629 min; peak area, 97% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(4-fluorophenyl)methanone (10a). Light-yellow solid; yield 
62% from 21 and 4-fluorobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.72-2.05 (m, 4H), 3.00-3.20 (bm, 
2H), 3.45-3.55 (m, 1H), 3.72-4.00 (bm, 1H), 4.50-4.70 (bm, 1H), 7.10 (double AA’XX’, 2H, 3JHF-o = 
9.5 Hz, JAX = 8.7 Hz, JAA’/XX’ = 2.4 Hz), 7.40-7.49 (m, 4H), 7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ 
= 2.2 Hz). 13C-NMR (CDCl3) δ (ppm): 28.63 (2C), 43.32, 115.69 (d, 2C, J = 22.1 Hz), 129.26 (2C), 
129.30 (d, 2C, J = 9.1 Hz), 129.78 (2C), 132.00 (d, J = 3.0 Hz), 134.00, 139.90, 163.49 (d, J = 249.5 
Hz), 169.65, 200.41. HPLC analysis: retention time = 12.464 min; peak area, 97% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-fluorophenyl)methanone (10b). Light-yellow solid; yield 
55% from 21 and 3-fluorobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.73-2.08 (m, 4H), 3.00-3.22 (bm, 
2H), 3.46-3.54 (m, 1H), 3.75-3.92 (bm, 1H), 4.58-4.74 (bm, 1H), 7.09-7.14 (m, 2H), 7.15 (dt, 1H, J 
= 7.8, 1.2 Hz), 7.36-7.42 (m, 1H), 7.46 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.89 (AA’XX’, 
2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz). 
13C-NMR (CDCl3) δ (ppm): 28.61 (2C), 43.26, 114.27 (d, J = 
22.1 Hz), 116.83, (d, J = 21.1 Hz), 122.60 (d, J = 3.0 Hz), 129.27 (2C), 129.79 (2C), 130.46 (d, J = 
8.0 Hz), 133.99, 138.06 (d, J = 7.0 Hz), 139.91, 162.65 (d, J = 248.5 Hz), 169.04, 200.37. HPLC 
analysis: retention time = 12.519 min; peak area, 99% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-fluorophenyl)methanone (10c). Light-yellow solid; yield 
64% from 21 and 2-fluorobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.73-1.87 (m, 3H), 1.98-2.06 (m, 
1H), 3.02-3.29 (m, 2H), 3.42-3.53 (m, 1H), 3.63-3.72 (m, 1H), 4.68-4.76 (m, 1H), 7.09 (t, 1H, J = 9.6 
Hz), 7.21 (td, 1H, J = 8.0, 0.9 Hz), 7.36-7.42 (m, 2H), 7.46 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.1 
Hz), 7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.1 Hz). 13C-NMR (CDCl3) δ (ppm): 28.55, 28.60, 
41.43, 43.32, 46.54, 115.89 (d, J = 21.1 Hz), 124.32 (d, J = 18.1 Hz), 124.83 (d, J = 3.0 Hz), 129.14 
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(d, J = 4.0 Hz), 129.27 (2C), 129.80 (2C), 131.38 (d, J = 8.0 Hz), 134.07, 139.86, 158.26 (d, J = 248.5 
Hz), 165.34, 200.42. HPLC analysis: retention time = 12.439 min; peak area, 98% (254 nm). 
(1-(4-Bromobenzoyl)piperidin-4-yl)(4-chlorophenyl)methanone (11a). Yellow solid; yield 65% 
from 21 and 4-bromobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.64-2.00 (m, 4H), 3.04-3.28 (bm, 
2H), 3.46-3.53 (m, 1H), 3.80-3.90 (bm, 1H), 4.58-4.70 (bm, 1H), 7.30 (AA’XX’, 2H, JAX = 8.4 Hz, 
JAA’/XX’ = 2.1 Hz), 7.46 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.2 Hz), 7.55 (AA’XX’, 2H, JAX = 8.4 
Hz, JAA’/XX’ = 2.1 Hz), 7.89 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.1 Hz).13C-NMR (CDCl3) δ (ppm): 
28.66 (2C), 43.33, 124.18, 128.78 (2C), 129.33 (2C), 129.83 (2C), 131.92 (2C), 134.02, 134.84, 
140.00, 169.58, 200.42. HPLC analysis: retention time = 13.127 min; peak area, 98% (254 nm). 
(1-(3-Bromobenzoyl)piperidin-4-yl)(4-chlorophenyl)methanone (11b). Yellow solid; yield 30% 
from 21 and 3-bromobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.74-2.03 (m, 4H), 3.05-3.20 (bm, 
2H), 3.47-3.54 (m, 1H), 3.78-3.90 (bm, 1H), 4.64-4.67 (bm, 1H), 7.27-7.35 (m, 2H), 7.47 (AA’XX’, 
2H, JAX = 8.6 Hz, JAA’/XX’ = 2.0 Hz), 7.55-7.57 (m, 2H), 7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 
2.1 Hz). 13C-NMR (CDCl3) δ (ppm): 28.66 (2C), 43.31, 122.83, 125.54, 129.34 (2C), 129.84 (2C), 
130.06, 130.32, 132.93, 134.02, 137.99, 140.00, 168.86, 200.41. HPLC analysis: retention time = 
13.126 min; peak area, 97% (254 nm). 
(1-(2-Bromobenzoyl)piperidin-4-yl)(4-chlorophenyl)methanone (11c). Orange solid; yield 57% 
from 21 and 2-bromobenzoic acid; 1H-NMR (CDCl3; asterisk denotes isomer peaks) δ (ppm): 1.65-
2.07 (m, 4H), 3.04-3.15 (m, 1H), 3.20-3.28 (m, 1H), 3.42-3.59 (m, 2H), 4.69-4.80 (m, 1H), 7.22-7.31 
(m, 2H), 7.34 (dd, 1H, J = 7.0, 1.1 Hz), 7.38* (dd, 1H, J = 8.3, 1.1 Hz), 7.44-7.48 (m, 2H), 7.56-7.61 
(m, 1H), 7.86-7.90 (m, 2H). 13C-NMR (CDCl3; asterisk denotes isomer peaks) δ (ppm): 28.36*, 28.39, 
28.60, 28.65*, 41.01, 41.18*, 43.21, 43.43*, 45.96*, 46.63, 119.21, 119.36*, 127.59*, 127.75, 
127.83, 127.97*, 129.28*, 129.31 (2C), 129.81 (2C), 130.34*, 130.45, 132.86*, 133.09, 134.04, 
134.09*, 138.18*, 138.31, 139.86, 139.95*, 167.74*, 167.89, 200.36*, 200.48. HPLC analysis: 
retention time = 12.798 min; peak area, 97% (254 nm). 
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(4-(4-Chlorobenzoyl)piperidin-1-yl)(4-iodophenyl)methanone (12a). Off-white solid; yield 72% 
from 21 and 4-iodobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.71-2.08 (m, 4H), 2.98-3.20 (bm, 2H), 
3.44-3.53 (m, 1H), 3.74-3.92 (bm, 1H), 4.57-4.72 (bm, 1H), 7.16 (AA’XX’, 2H, JAX = 8.4 Hz, JAA’/XX’ 
= 2.0 Hz), 7.46 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz), 7.76 (AA’XX’, 2H, JAX = 8.4 Hz, 
JAA’/XX’ = 2.0 Hz), 7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz). 13C-NMR (CDCl3) δ (ppm): 
28.61 (2C), 43.26, 95.97, 128.74 (2C), 129.27 (2C), 129.78 (2C), 133.99, 135.39, 137.79 (2C), 
139.91, 169.60, 200.36. HPLC analysis: retention time = 13.341 min; peak area, 99% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-iodophenyl)methanone (12b). Light-yellow solid; yield 
51% from 21 and 3-iodobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.73-2.08 (m, 4H), 3.00-3.23 (bm, 
2H), 3.46-3.55 (m, 1H), 3.75-3.90 (bm, 1H), 4.57-4.73 (bm, 1H), 7.15 (dd, 1H, J = 8.4, 7.6 Hz), 7.37 
(dt, 1H, J = 7.9, 1.3 Hz), 7.47 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.74-7.78 (m, 2H), 7.89 
(AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz). 13C-NMR (CDCl3) δ (ppm): 28.62 (2C), 43.27, 94.38, 
126.05, 129.30 (2C), 129.81 (2C), 130.34, 134.01, 135.79, 138.05, 138.79, 139.94, 168.66, 200.37. 
HPLC analysis: retention time = 13.301 min; peak area, 98% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-iodophenyl)methanone (12c). Yellow solid; yield 57% 
from 21 and 2-iodobenzoic acid; 1H-NMR (CDCl3; asterisk denotes isomer peaks) δ (ppm): 1.65-2.15 
(m, 4H), 3.05-3.15 (m, 1H), 3.20-3.30 (m, 1H), 3.45-3.60 (m, 2H), 4.68-4.80 (m, 1H), 7.05-7.11 (m, 
1H), 7.18* (dd, 1H, J = 7.6, 1.6 Hz), 7.24 (dd, 1H, J = 7.6, 1.6 Hz), 7.36-7.43 (m, 1H), 7.44-7.48 (m, 
2H), 7.81-7.86 (m, 1H), 7.86-7.91 (m, 2H). 1H-NMR (DMSO-d6; asterisk denotes isomer peaks) δ 
(ppm): 1.38-1.65 (m, 2H), 1.67-1.80 (m, 1H), 1.85-1.96 (m, 1H), 2.93-3.05 (m, 1H), 3.09-3.30 (m, 
2H), 3.70-3.82 (m, 1H), 4.47-4.60 (m, 1H), 7.12-7.19 (m, 1H), 7.24* (dd, 1H, J = 7.4, 1.2 Hz), 7.29 
(dd, 1H, J = 7.5, 1.3 Hz), 7.43-7.49 (m, 1H), 7.58-7.64 (m, 2H), 7.85-7.90 (m, 1H), 7.90-8.05 (m, 
2H). 1H-NMR (DMSO-d6; 80 °C) δ (ppm): 1.50-1.80 (bm, 3H), 1.88-1.99 (bm, 1H), 3.00-3.35 (bm, 
3H), 3.68-3.77 (m, 1H), 4.44-4.55 (bm, 1H), 7.15 (td, 1H, J = 7.7, 1.7 Hz), 7.23-7.27 (bm, 1H), 7.46 
(td, 1H, J = 7.5, 1.1 Hz), 7.58 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.3 Hz), 7.88 (dd, 1H, J = 7.9, 
0.8 Hz), 8.00 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz). 13C-NMR (CDCl3; asterisk denotes 
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isomer peaks) δ (ppm): 28.26*, 28.37, 28.61, 28.66*, 41.06, 41.20*, 43.24, 43.45*, 46.13, 46.71*, 
92.44, 92.70*, 126.87*, 127.20, 128.42*, 128.68, 129.30*, 129.33, 129.83 (3C), 130.31*, 130.39, 
134.03, 134.08*, 139.25, 139.57*, 139.90*, 139.98, 142.43, 142.56*, 169.42*, 169.52, 200.38*, 
200.49. 13C-NMR (DMSO-d6; asterisk denotes isomer peaks) δ (ppm): 27.77, 27.94*, 28.07*, 28.36, 
40.20, 42.24*, 42.38, 45.40*, 45.94, 92.90, 93.17*, 126.79, 126.98*, 128.29, 128.47*, 128.92 (4C), 
130.17, 130.21*, 134.01, 138.15, 138.58*, 138.88, 142.30, 142.41*, 167.98, 168.09*, 200.77*, 
200.79. 13C-NMR (DMSO-d6; 80 °C) δ (ppm): 27.36, 27.83, 42.05, 45.30, 92.00, 126.58, 127.94, 
128.46 (2C), 129.64 (2C), 129.73, 134.05, 137.73, 138.45, 142.17, 167.75, 200.42. HPLC analysis: 
retention time = 12.972 min; peak area, 99% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(p-tolyl)methanone (13a). Yellow solid; yield 50% from 21 
and p-toluic acid; 1H-NMR (CDCl3) δ (ppm): 1.74-2.00 (m, 4H), 2.38 (s, 3H), 2.95-3.16 (bm, 2H), 
3.44-3.55 (m, 1H), 3.80-4.15 (bm, 1H), 4.45-4.53 (bm, 1H), 7.19-7.22 (m, 2H), 7.29-7.33 (m, 2H), 
7.46 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.1 Hz), 7.89 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.1 
Hz). 13C-NMR (CDCl3) δ (ppm): 21.49, 28.71 (2C), 43.49, 127.13 (2C), 129.21 (2C), 129.26 (2C), 
129.82 (2C), 133.05, 134.10, 139.85, 139.96, 170.80, 200.56. HPLC analysis: retention time = 12.754 
min; peak area, 97% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(m-tolyl)methanone (13b). Orange solid; yield 51% from 21 
and m-toluic acid; 1H-NMR (CDCl3) δ (ppm): 1.74-2.00 (m, 4H), 2.37 (s, 3H), 3.00-3.18 (bm, 2H), 
3.45-3.53 (m, 1H), 3.80-4.00 (bm, 1H), 4.55-4.80 (bm, 1H), 7.77-7.24 (m, 3H), 7.28 (t, 1H, J = 7.8 
Hz), 7.46 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz), 7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 
2.2 Hz). 13C-NMR (CDCl3) δ (ppm): 21.47, 28.70 (2C), 43.47, 123.85, 127.55, 128.43 (2C), 129.26 
(2C), 129.80, 130.48, 134.08, 136.02, 138.53, 139.86, 170.77, 200.54. HPLC analysis: retention time 
= 12.766 min; peak area, 96% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(o-tolyl)methanone (13c). Orange solid; yield 46% from 21 
and o-toluic acid; 1H-NMR (CDCl3; asterisk denotes isomer peaks) δ (ppm): 1.68-1.85 (m, 3H), 1.98-
2.08 (m, 1H), 2.30* (s, 3H), 2.34 (s, 3H), 2.97-3.16 (m, 2H), 3.42-3.55 (m, 1H), 3.56-3.65 (m, 1H), 
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4.70-4.83 (m, 1H), 7.11-7.30 (m, 4H), 7.46 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.88 
(AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.0 Hz). 13C-NMR (CDCl3; asterisk denotes isomer peaks) δ 
(ppm): 19.10, 19.21*, 28.55*, 28.81, 28.95*, 40.98, 43.30*, 43.53, 46.11*, 46.48, 125.81, 125.96*, 
126.16, 128.99, 129.29 (2C), 129.79 (2C), 130.49, 130.66*, 134.05, 134.10, 134.41*, 136.32, 139.92, 
170.07*, 179.17, 200.46, 200.56*. HPLC analysis: retention time = 12.588 min; peak area, 97% (254 
nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(4-(trifluoromethyl)phenyl)methanone (14a). Orange solid; 
yield 54% from 21 and 4-(trifluoromethyl)benzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.73-2.10 (m, 
4H), 3.02-3.24 (bm, 2H), 3.48-3.56 (m, 1H), 3.71-3.83 (bm, 1H), 4.61-4.75 (bm, 1H), 7.47 (AA’XX’, 
2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.51-7.55 (m, 2H), 7.67-7.71 (m, 2H), 7.89 (AA’XX’, 2H, JAX = 
8.7 Hz, JAA’/XX’ = 2.2 Hz). 
13C-NMR (CDCl3) δ (ppm): 28.64 (2C), 43.22, 123.84 (q, J = 272.7 Hz), 
125.79 (q, 2C, J = 4.0 Hz), 127.37, 129.33 (2C), 129.82 (2C), 131.81 (q, J = 32.2 Hz), 133.99, 139.63 
(q, 2C, J = 1.0 Hz), 140.02, 169.08, 200.33. HPLC analysis: retention time = 13.273 min; peak area, 
96% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-(trifluoromethyl)phenyl)methanone (14b). Orange solid; 
yield 41% from 21 and 3-(trifluoromethyl)benzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.74-2.09 (m, 
4H), 3.02-3.28 (bm, 2H), 3.46-3.57 (m, 1H), 3.70-3.88 (bm, 1H), 4.58-4.76 (bm, 1H), 7.47 (AA’XX’, 
2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz), 7.55 (t, 1H, J = 8.3 Hz), 7.59-7.63 (m, 1H), 7.67-7.71 (m, 2H), 
7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz). 13C-NMR (CDCl3) δ (ppm): 28.59 (2C), 43.19, 
123.77 (q, J = 273.7 Hz), 124.04, 126.59, 129.29 (3C), 129.80 (2C), 130.30, 131.24 (q, J = 33.2 Hz), 
133.98, 136.82, 139.97, 168.95, 200.31. HPLC analysis: retention time = 13.234 min; peak area, 98% 
(254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-(trifluoromethyl)phenyl)methanone (14c). Orange solid; 
yield 55% from 21 and 2-(trifluoromethyl)benzoic acid; 1H-NMR (CDCl3; asterisk denotes isomer 
peaks) δ (ppm): 1.65-1.84 (m, 2H), 1.97-2.08 (m, 2H), 3.03-3.18 (m, 2H), 3.40-3.53 (m, 2H), 4.68-
4.77 (m, 1H), 7.32* (d, 1H, J = 7.8 Hz), 7.37 (d, 1H, J = 7.6 Hz), 7.43-7.48 (m, 2H), 7.49-7.55 (m, 
38 
 
1H), 7.57-7.63 (m, 1H), 7.69-7.73 (m, 1H), 7.85-7.90 (m, 2H). 13C-NMR (CDCl3; asterisk denotes 
isomer peaks) δ (ppm): 27.77*, 28.16, 28.23*, 28.62, 41.10, 41.16*, 43.17, 43.20*, 46.60, 46.63*, 
123.77* (q, J = 274.2 Hz), 123.80 (q, J = 273.7 Hz), 126.71 (q, J = 4.7 Hz), 126.73 (q, J = 31.9 Hz), 
126.94* (q, J = 5.0 Hz), 127.22*, 127.25, 128.56, 128.93*, 129.26 (2C), 129.31* (2C), 129.79* (2C), 
129.81 (2C), 132.20*, 132.44, 133.98, 134.05*, 135.01* (q, J = 2.0 Hz), 135.10 (q, J = 2.0 Hz), 
139.83*, 139.98, 167.41*, 167.56, 200.20*, 200.48. HPLC analysis: retention time = 13.008 min; 
peak area, 96% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-methoxyphenyl)methanone (15b). White solid; yield 67% 
from 21 and 3-methoxybenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.72-2.02 (m, 4H), 3.00-3.20 (bm, 
2H), 3.45-3.53 (m, 1H), 3.82 (s, 3H), 3.80-3.95 (bm, 1H), 4.60-4.75 (bm, 1H), 6.93-6.98 (m, 3H), 
7.28.7.33 (m, 1H), 7.46 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 7.89 (AA’XX’, 2H, JAX = 8.8 
Hz, JAA’/XX’ = 2.2 Hz). 
13C-NMR (CDCl3) δ (ppm): 28.71 (2C), 43.46, 55.50, 112.32, 115.73, 119.01, 
129.30 (2C), 129.76, 129.82 (2C), 134.11, 137.36, 139.91, 159.83, 170.34, 200.53. HPLC analysis: 
retention time = 12.387 min; peak area, 97% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-methoxyphenyl)methanone (15c). Orange solid; yield 
36% from 21 and 2-methoxybenzoic acid; 1H-NMR (CDCl3; asterisk denotes isomer peaks) δ (ppm): 
1.70-2.05 (m, 4H), 2.97-3.20 (m, 2H), 3.40-3.50 (m, 1H), 3.57-3.65 (m, 1H), 3.84* (s, 3H), 3.85 (s, 
3H), 4.72-4.81 (m, 1H), 6.89-6.93 (m, 1H), 6.96-7.02 (m, 1H), 7.21-7.25 (m, 1H), 7.32-7.37 (m, 1H), 
7.43-7.48 (m, 2H), 7.86-7.91 (m, 2H). 13C-NMR (CDCl3; asterisk denotes isomer peaks) δ (ppm): 
28.63, 28.70*, 41.13*, 41.23, 43.55, 43.63*, 46.12*, 46.74, 55.66, 55.74*, 110.99*, 111.08, 121.01*, 
121.15, 125.92, 126.03*, 127.94, 128.05*, 129.26 (2C), 129.81 (2C), 130.50*, 130.54, 134.17, 
139.82, 139.84*, 155.44*, 155.51, 167.87*, 168.09, 200.61, 200.70*. HPLC analysis: retention time 
= 12.219 min; peak area, 95% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(4-(trifluoromethoxy)phenyl)methanone (16a). Orange 
solid; yield 54% from 21 and 4-(trifluoromethoxy)benzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.74-
2.07 (m, 4H), 3.01-3.23 (bm, 2H), 3.46-3.55 (m, 1H), 3.74-3.95 (bm, 1H), 4.53-4.76 (bm, 1H), 7.24-
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7.28 (m, 2H), 7.44-7.49 (m, 4H), 7.89 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.0 Hz). 13C-NMR 
(CDCl3) δ (ppm): 28.65 (2C), 43.28, 120.49 (q, J = 258.2 Hz), 121.06 (2C), 128.87 (2C), 129.31 (2C), 
129.81 (2C), 134.03, 134.60, 139.97, 150.17 (q, J = 1.3 Hz), 169.28, 200.38. HPLC analysis: retention 
time = 13.405 min; peak area, 98% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-(trifluoromethoxy)phenyl)methanone (16b). Orange 
solid; yield 47% from 21 and 3-(trifluoromethoxy)benzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.74-
2.10 (m, 4H), 3.00-3.25 (bm, 2H), 3.45-3.55 (m, 1H), 3.72-3.90 (bm, 1H), 4.58-4.73 (bm, 1H), 7.25-
7.30 (m, 2H), 7.35 (d, 1H, J = 7.6 Hz), 7.43-7.49 (m, 3H), 7.87-7.91 (m, 2H).  13C-NMR (CDCl3) δ 
(ppm): 28.60 (2C), 43.25, 119.73, 120.52 (q, J = 257.9 Hz), 122.24, 125.37, 129.31 (2C), 129.81 
(2C), 130.34, 134.03, 137.94, 139.98, 149.32 (q, J = 2.0 Hz), 168.78, 200.34. HPLC analysis: 
retention time = 13.420 min; peak area, 97% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-(trifluoromethoxy)phenyl)methanone (16c). Orange 
solid; yield 50% from 21 and 2-(trifluoromethoxy)benzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.70-
2.04 (m, 4H), 3.02-3.26 (m, 2H), 3.40-3.62 (m, 2H), 4.68-4.78 (m, 1H), 7.28-7.48 (m, 6H), 7.89 
(AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.1 Hz). 13C-NMR (CDCl3; asterisk denotes isomer peaks) δ 
(ppm): 28.36*, 28.46, 28.52*, 28.63, 41.19, 41.39*, 43.17, 43.35*, 46.17, 46.68*, 120.55 (q, J = 
258.6 Hz), 120.61, 120.68*,127.30*, 127.38, 128.75, 128.85*, 129.30, 129.81 (4C), 130.80, 134.02, 
134.07*, 139.83*, 139.97, 145.00, 165.62, 200.22*, 200.47. HPLC analysis: retention time = 13.205 
min; peak area, 97% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(4-hydroxyphenyl)methanone (17a). Beige solid; yield 69% 
from 4; 1H-NMR (DMSO-d6) δ (ppm): 1.43-1.55 (m, 2H), 1.76-1.87 (m, 2H), 2.99-3.16 (bm, 2H), 
3.73 (tt, 1H, J = 11.1, 3.5 Hz), 3.95-4.30 (bm, 2H), 6.77 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.4 
Hz), 7.25 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.4 Hz), 7.61 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 
2.2 Hz), 8.02 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.3 Hz), 9.82 (exchangeable bs, 1H). 13C-NMR 
(DMSO-d6) δ (ppm): 28.29 (2C), 42.49, 114.85 (2C), 126.37, 128.94 (2C), 128.95 (2C), 130.18 (2C), 
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134.12, 138.13, 158.58, 169.33, 200.93. HPLC analysis: retention time = 11.077 min; peak area, 99% 
(254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-hydroxyphenyl)methanone (17b). White solid; yield 94% 
from 15b; 1H-NMR (acetone-d6) δ (ppm): 1.59-1.71 (m, 2H), 1.81-2.00 (bm, 2H), 2.90-3.30 (bm, 
2H), 3.79 (tt, 1H, J = 11.3, 3.7 Hz), 4.40-4.70 (bm, 2H), 6.85-6.92 (m, 3H), 7.23-7.28 (m, 1H), 7.57 
(AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz), 8.07 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.3 Hz), 
8.58 (exchangeable bs, 1H). 13C-NMR (acetone-d6) δ (ppm): 44.02, 114.62, 117.12, 118.71, 129.83 
(2C), 130.40, 131.00 (2C), 135.55, 139.11, 139.59, 158.27, 170.14, 201.33. HPLC analysis: retention 
time = 11.262 min; peak area, 99% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-hydroxyphenyl)methanone (17c). Grey solid; yield 76% 
from 15c; 1H-NMR (acetone-d6) δ (ppm): 1.66-1.78 (m, 2H), 1.92-2.00 (m, 2H), 3.17-3.28 (m, 2H), 
3.81 (tt, 1H, J = 11.2, 3.7 Hz), 4.22-4.35 (bm, 2H), 6.87-6.95 (m, 2H), 7.27-7.32 (m, 2H), 7.57 
(AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz), 8.07 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ = 2.2 Hz), 
9.33 (exchangeable s, 1H). 13C-NMR (acetone-d6) δ (ppm): 43.95, 117.48, 119.93, 122.03, 129.35, 
129.84 (2C), 131.01, 132.10 (2C), 135.56, 139.60, 157.19, 169.72, 201.31. HPLC analysis: retention 
time = 11.492 min; peak area, 99% (254 nm). 
(1-(4-Aminobenzoyl)piperidin-4-yl)(4-chlorophenyl)methanone (18a). Beige solid; yield 77% 
from 31; 1H-NMR (acetone-d6) δ (ppm): 1.58-1.70 (m, 2H), 1.86-1.94 (m, 2H), 3.06-3.16 (m, 2H), 
3.76 (tt, 1H, J = 11.3, 3.8 Hz), 4.22-4.32 (bm, 1H), 4.93-5.03 (bm, 1H), 6.67 (AA’XX’, 2H, JAX = 8.6 
Hz, JAA’/XX’ = 2.3 Hz), 7.21 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.2 Hz), 7.57 (AA’XX’, 2H, JAX = 
8.8 Hz, JAA’/XX’ = 2.3 Hz), 8.06 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz). 13C-NMR (acetone-d6) 
δ (ppm): 44.17, 114.00 (2C), 119.92, 129.02. 129.79 (2C), 130.03 (2C), 130.98 (2C), 135.55, 139.51, 
171.15, 201.40.  HPLC analysis: retention time = 11.037 min; peak area, 98% (254 nm). 
(1-(3-Aminobenzoyl)piperidin-4-yl)(4-chlorophenyl)methanone (18b). Beige solid; yield 89% 
from 30; 1H-NMR (acetone-d6) δ (ppm): 1.57-1.68 (m, 2H), 1.83-1.95 (bm, 2H), 2.90-3.30 (bm, 2H), 
3.78 (tt, 1H, J = 11.2, 3.7 Hz), 4.76-4.82 (bm, 2H), 6.60 (dt, 1H, J = 7.5, 1.3 Hz), 6.69-6.73 (m, 2H), 
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7.09 (dd, 1H, J = 8.7, 7.5 Hz), 7.57 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.3 Hz), 8.06 (AA’XX’, 
2H, JAX = 8.8 Hz, JAA’/XX’ = 2.2 Hz). 
13C-NMR (acetone-d6) δ (ppm): 44.08, 113.35, 115.69, 115.86, 
129.77, 129.82 (2C), 130.99 (2C), 135.55, 138.56, 139.57, 149.44, 170.83, 201.37. HPLC analysis: 
retention time = 11.188 min; peak area, 99% (254 nm). 
 (1-(2-Aminobenzoyl)piperidin-4-yl)(4-chlorophenyl)methanone (18c). Orange solid; yield 44% 
from 21 and anthranilic acid; 1H-NMR (acetone-d6) δ (ppm): 1.62-1.73 (m, 2H), 1.88-1.97 (m, 2H), 
3.10-3.21 (m, 2H), 3.78 (tt, 1H, J = 11.3, 3.7 Hz), 4.14-4.32 (bm, 1H), 4.87-4.95 (bm, 1H), 6.62 (td, 
1H, J = 7.4, 1.0 Hz), 6.78 (dd, 1H, J = 8.1, 0.7 Hz), 7.07-7.14 (m, 2H), 7.57 (AA’XX’, 2H, JAX = 8.8 
Hz, JAA’/XX’ = 2.2 Hz), 8.06 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.3 Hz). 13C-NMR (acetone-d6) δ 
(ppm): 44.06, 116.84, 116.94, 120.83, 128.61, 129.79, 129.80 (2C), 130.98 (2C), 135.53, 139.54, 
147.44, 170.21, 201.32. HPLC analysis: retention time = 11.795 min; peak area, 95% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(4-nitrophenyl)methanone (19a). Yellow solid; yield 48% 
from 21 and 4-nitrobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.74-2.10 (m, 4H), 3.04-3.28 (bm, 2H), 
3.49-3.59 (m, 1H), 3.66-3.80 (bm, 1H), 4.61-4.73 (bm, 1H), 7.47 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ 
= 2.2 Hz), 7.59 (AA’XX’, 2H, JAX = 8.9 Hz, JAA’/XX’ = 2.1 Hz), 7.89 (AA’XX’, 2H, JAX = 8.8 Hz, 
JAA’/XX’ = 2.2 Hz), 8.29 (AA’XX’, 2H, JAX = 8.8 Hz, JAA’/XX’ = 2.1 Hz). 13C-NMR (CDCl3) δ (ppm): 
28.61 (2C), 43.10, 124.05 (2C), 128.05 (2C), 129.35 (2C), 129.80 (2C), 134.07, 140.08, 142.25, 
148.65, 168.19, 200.16. HPLC analysis: retention time = 12.470 min; peak area, 99% (254 nm). 
(4-(4-Chlorobenzoyl)piperidin-1-yl)(3-nitrophenyl)methanone (19b). Orange solid; yield 55% 
from 21 and 3-nitrobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.77-2.10 (m, 4H), 3.08-3.30 (bm, 2H), 
3.49-3.58 (m, 1H), 3.72-3.85 (bm, 1H), 4.58-4.73 (bm, 1H), 7.47 (AA’XX’, 2H, JAX = 8.7 Hz, JAA’/XX’ 
= 2.2 Hz), 7.63 (td, 1H, J = 7.6, 1.3 Hz), 7.77 (dt, 1H, J = 7.7, 1.3 Hz), 7.89 (AA’XX’, 2H, JAX = 8.7 
Hz, JAA’/XX’ = 2.2 Hz), 8.27-8.31 (m, 2H). 
13C-NMR (CDCl3) δ (ppm): 28.55 (2C), 43.03, 122.22, 
124.62, 129.31 (2C), 129.79 (2C), 129.96, 133.03, 133.94, 137.60, 139.99, 148.21, 167.84, 200.20. 
HPLC analysis: retention time = 12.445 min; peak area, 96% (254 nm). 
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(4-(4-Chlorobenzoyl)piperidin-1-yl)(2-nitrophenyl)methanone (19c). Light-yellow solid; yield 
54% from 21 and 2-nitrobenzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.71-1.86 (bm, 3H), 2.02-2.13 (bm, 
1H), 3.10-3.25 (bm, 2H), 3.42-3.56 (bm, 2H), 4.57-4.76 (bm, 1H), 7.36-7.48 (m, 3H), 7.57 (td, 1H, J 
= 8.5, 1.3 Hz), 7.68-7.75 (m, 1H), 7.84-7.91 (m, 2H), 8.20 (d, 1H, J = 8.2 Hz). 13C-NMR (CDCl3) δ 
(ppm): 27.96, 28.38, 41.27, 43.01, 46.01, 124.95, 128.12, 129.33, 129.83 (3C), 129.96, 133.16, 
134.05, 134.78, 140.00, 145.30, 166.90, 200.58. HPLC analysis: retention time = 12.240 min; peak 
area, 97% (254 nm). 
(1-Benzoylpiperidin-4-yl)(4-chlorophenyl)methanone (20). Light-yellow solid; yield 61% from 21 
and benzoic acid; 1H-NMR (CDCl3) δ (ppm): 1.70-2.00 (m, 4H). 2.97-3.23 (bm, 2H), 3.45-3.53 (m, 
1H), 3.80-3.95 (bm, 1H), 4.57-4.70 (bm, 1H), 7.41 (s, 5H), 7.46 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ 
= 2.1 Hz), 7.89 (AA’XX’, 2H, JAX = 8.6 Hz, JAA’/XX’ = 2.1 Hz). 13C-NMR (CDCl3) δ (ppm): 28.71 
(2C), 43.47, 127.00 (2C), 128.64 (2C), 129.30, 129.82 (4C), 134.11, 136.09, 139.92, 170.62, 200.52. 
HPLC analysis: retention time = 12.259 min; peak area, 98% (254 nm). 
(4-([1,1'-Biphenyl]-4-carbonyl)piperidin-1-yl)(3-hydroxyphenyl)methanone (43). White solid; 
yield 82% from 44; 1H-NMR (DMSO-d6) δ (ppm): 1.46-1.59 (m, 2H), 1.72-1.98 (bm, 2H), 2.90-3.10 
(bm, 1H), 3.10-3.30 (bm, 1H), 3.60-3.75 (bm, 1H), 3.80 (tt, 1H, J = 11.2, 3.4 Hz), 4.40-4.57 (bm, 
1H), 6.74-6.80 (m, 2H), 6.82 (ddd, 1H, J = 8.1, 2.5, 1.0 Hz), 7.23 (t, 1H, J = 7.7 Hz), 7.44 (tt, 1H, J 
= 7.3, 1.5 Hz), 7.48-7.54 (m, 2H), 7.73-7.78 (m, 2H), 7.82-7.87 (m, 2H), 8.08-8.12 (m, 2H), 9.67 
(exchangeable s, 1H). 9.82 (exchangeable bs, 1H). 13C-NMR (DMSO-d6) δ (ppm): 42.43, 113.40, 
116.31, 117.09, 127.03 (2C), 127.07 (2C), 128.44, 129.04 (2C), 129.12 (2C), 129.62, 134.24, 137.51, 
138.88, 144.66, 157.29, 168.95, 201.46. HPLC analysis: retention time = 12.153 min; peak area, 99% 
(254 nm). 
Docking Calculations. The crystal structure of hMAGL (pdb code 3PE620) was taken from the 
Protein Data Bank.29 After adding hydrogen atoms the protein complexed with its reference inhibitor 
was minimized using Amber14 software30 and ff14SB force field at 300 K. The complex was placed 
in a rectangular parallelepiped water box, an explicit solvent model for water, TIP3P, was used and 
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the complex was solvated with a 10 Å water cap. Sodium ions were added as counter ions to neutralize 
the system. Two steps of minimization were then carried out; in the first stage, we kept the protein 
fixed with a position restraint of 500 kcal/mol Å2 and we solely minimized the positions of the water 
molecules. In the second stage, we minimized the entire system through 5000 steps of steepest descent 
followed by conjugate gradient (CG) until a convergence of 0.05 kcal/Å•mol. The ligands were built 
using Maestro31 and were minimized by means of Macromodel32 in a water environment using the 
CG method until a convergence value of 0.05 kcal/Å mol, using the MMFFs force field and a 
distance-dependent dielectric constant of 1.0. Automated docking was carried out by means of the 
AUTODOCK 4.0 program;33 Autodock Tools34 was used in order to identify the torsion angles in the 
ligands, add the solvent model and assign the Kollman atomic charges to the protein. The ligand 
charge was calculated using the Gasteiger method. The regions of interest used by Autodock were 
defined by considering the ZYH reference inhibitor as the central group; in particular, a grid of 82, 
40, and 30 points in the x, y, and z directions was constructed centered on the center of the mass of 
this compound. A grid spacing of 0.375 Å and a distance-dependent function of the dielectric constant 
were used for the energetic map calculations. Using the Lamarckian Genetic Algorithm, the docked 
compounds were subjected to 100 runs of the Autodock search, using 500000 steps of energy 
evaluation and the default values of the other parameters. Cluster analysis was performed on the 
results using an RMS tolerance of 2.0 Å.  
MD Simulations. All simulations were performed using AMBER, version 14.30 MD simulations 
were carried out using the ff14SB force field at 300 K. The complex was placed in a rectangular 
parallelepiped water box. An explicit solvent model for water, TIP3P, was used, and the complex was 
solvated with a 20 Å water cap. Sodium ions were added as counterions to neutralize the system. 
Prior to MD simulations, two steps of minimization were carried out using the same procedure 
described above. Particle Mesh Ewald (PME) electrostatics and periodic boundary conditions were 
used in the simulation.35 The MD trajectory was run using the minimized structure as the starting 
conformation. The time step of the simulations was 2.0 fs with a cutoff of 10 Å for the nonbonded 
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interaction, and SHAKE was employed to keep all bonds involving hydrogen atoms rigid. Constant-
volume periodic boundary MD was carried out for 1.0 ns, during which the temperature was raised 
from 0 to 300 K. Then 50 ns of constant pressure periodic boundary MD was carried out at 300 K 
using the Langevin thermostat to maintain constant the temperature of our system. All the α carbons 
of the protein were blocked with a harmonic force constant of 10 kcal/mol•Å2. General Amber force 
field (GAFF) parameters were assigned to the ligand, while partial charges were calculated using the 
AM1-BCC method as implemented in the Antechamber suite of AMBER 14. The final structure of 
the complex was obtained as the average of the last 50.0 ns of MD minimized by the CG method until 
a convergence of 0.05 kcal/mol•Å2. The average structure was obtained using the Cpptraj program36 
implemented in AMBER 14. 
MAGL inhibition assay. Human recombinant MAGL, 1, 2 and 4-NPA substrate were from Cayman 
Chemical. The IC50 values for compounds were generated in 96-well microtiter plates. The MAGL 
reaction was conducted at room temperature at a final volume of 200 μL in 10 mM Tris buffer, pH 
7.2, containing 1 mM EDTA and BSA 0.1 mg/ml. A total of 150 μL of 4-NPA 133.3 μM was added 
to 10 μL of DMSO containing the appropriate amount of compound. The reaction was initiated by 
the addition of 40 μL of MAGL (11 ng/well) in such a way that the assay was linear over 30 min. The 
final concentration of the analyzed compounds ranged for 1 and 2 from 10 to 0.00001 μM and for the 
other compounds from 200 to 0.0128 μM. After the reaction had proceeded for 30 min, absorbance 
values were then measured by using a Victor X3 Microplates Reader (PerkinElmer®) at 405 nm.5 
Two reactions were also run: one reaction containing no compounds and the second one containing 
neither inhibitor nor enzyme. IC50 values were derived from experimental data using the Sigmoidal 
dose−response fitting of GraphPad Prism software. To remove possible false positive results, for each 
compound concentration a blank analysis was carried out, and the final absorbance results were 
obtained detracting the absorbance produced by the presence of all the components except MAGL in 
the same conditions. In the enzyme kinetics experiments, compound was tested in the presence of 
scalar concentrations of 4-NPA. It was added in scalar amounts (concentration range = 1–10 μM) to 
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a reaction mixture containing Tris buffer and scalar concentrations of 4-NPA (15–1400 μM). Finally, 
MAGL solution was added (11 ng/well). The MAGL activity was measured by recording the increase 
in 4-nitrophenol absorbance using the Victor X3 Microplates Reader (PerkinElmer®). The 
experimental data were analyzed by non-linear regression analysis with GraphPad Prism software, 
using a second order polynomial regression analysis, and by applying the mixed-model inhibition fit. 
FAAH inhibition assay. The IC50 values for compounds were generated in 96-well microtiter plates. 
The FAAH reaction was conducted at room temperature at a final volume of 200 μL in 125 mM Tris 
buffer, pH 9.0, containing 1 mM EDTA and in the presence of BSA 0.1 mg/ml. A total of 150 μL of 
AMC arachidonoylamide 13.3 μM (final concentration = 10 μM) was added to 10 μL of DMSO 
containing the appropriate amount of compound. The reaction was initiated by the addition of 40 μL 
of FAAH (0.9 µg/well) in such a way that the assay was linear over 30 min. The final concentration 
of the analyzed compounds ranged for from 200 to 0.0128 µM. After the reaction had proceeded for 
30 min, fluorescence values were then measured by using a Victor X3 PerkinElmer instrument at an 
excitation wavelength of 340 nm and an emission of 460 nm. Two reactions were also run: one 
reaction containing no compounds and the second one containing neither inhibitor nor enzyme. IC50 
values were derived from experimental data using the Sigmoidal dose−response fitting of GraphPad 
Prism software. To remove possible false positive results, for each compound concentration a blank 
analysis was carried out, and the final fluorescence results were obtained detracting the fluorescence 
produced by the presence of all the components except FAAH in the same conditions. 
Cell viability assay. OVSAHO, OVCAR3, COV318, CAOV3 and MRC5 (from ATCC) were 
maintained at 37 °C in a humidified atmosphere containing 5% CO2 accordingly to the supplier. 
Normal (1.5 × 104) and tumor (5 × 102) cells were plated in 96-well culture plates. The day after 
seeding, vehicle or compounds were added at different concentrations to the medium. Compounds 
were added to the cell culture at a concentration ranging from 200 to 0.02 µM. Cell viability was 
measured after 96 h according to the supplier (Promega, G7571) with a Tecan F200 instrument. IC50 
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values were calculated from logistical dose response curves. Averages were obtained from three 
independent experiments, and error bars are standard deviations (n = 3). 
Western blot analysis. Cancer cells were pelleted and resuspended into RIPA buffer supplemented 
3 with a protease inhibitor mixture (Complete-EDTA, Roche, Switzerland) for protein extraction.37 
Fifty μg of proteins were run in 8% denaturating polyacrylamide gel. After electrophoresis, the 
proteins were transferred on nitrocellulose membrane (Whatman International Ltd, UK). The 
membranes were blocked with 5% (w/v) skim milk in Tris-buffered saline Tween 20 solution (TBS-
T) and incubated overnight with primary antibodies (Vinculin (sc-7649), 1:1000 from Santa Cruz, 
CA, US; MAGL (Ab24701) 1:1000 from Abcam, Cambridge, UK). After washing, membranes were 
incubated for 1 h with secondary antibodies in 5% milk TBS-T at RT, developed with enhanced 
chemiluminescence (ECL) solution and visualized with ChemiDoc Imager instrument (Bio-Rad 
Laboratories, CA, US).38 
 
SUPPORTING INFORMATION 
Clustering analysis, docking results of compound 17c and 17a, MD simulation analysis of 17b, 1H-
NMR spectra of compound 12c, interference analysis for compound 17b, effect of DTT on the 17b 
inhibition properties, cell growth inhibitory activities of compounds 17b, 2 and 3, IC50 plot of MAGL 
inhibition of compound 43, analytical data on intermediate compounds, HPLC chromatograms and 
NMR spectra of the final compounds. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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ABBREVIATIONS USED 
MAGL, monoacylglycerol lipase; AEA, anandamide; 2-AG, 2-arachidonoylglycerol; EAE, 
experimental allergic encephalomyelitis; FAAH, fatty acid amide hydrolase; PAINS, pan assay 
interference compounds; 4-NPA, 4-nitrophenylacetate; 4-NP, 4-nitrophenol; CG, conjugate gradient; 
PME, Particle Mesh Ewald; GAFF, general Amber force field; ECL, enhanced chemiluminescence. 
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